



Uscom Limited
ABN 35 091 028 090
Suite 1, Level 7, 10 Loftus Street
Sydney NSW 2000 Australia
T +612 9247 4144 F +612 9247 8157
www.uscom.com.au

MARKET ANNOUNCEMENT

USCOM used to reduce mortality in septic shock by 90%

Thursday 2nd of August 2012: Uscom (ASX code: UCM).

Uscom Ltd today confirms the announcement by the Bathurst Base Hospital, Greater Western Area Health Service of NSW Health, Australia, that a new strategy combining USCOM and advanced clinical protocols to treat septic shock has reduced mortality by 90% and emergency transport costs by 90%.

The data from 479 Bathurst septic shock patients collected over a 6 year period by The Australian and New Zealand Intensive Care Society Centre for Outcomes and Resource Evaluation (ANZICS CORE) were analysed. The ANZICS CORE database is collected from Intensive Care Units in Australian, New Zealand and Hong Kong and used to benchmark standards of care against comparable units and international standards.

Professor Brendan Smith and Senior Lecturer Veronica Madigan from the Charles Sturt University have been working with the critical care team at Bathurst Base Hospital and researchers from the University of Queensland to develop new concepts around the use of USCOM to treat septic shock. The new method, based on early diagnosis and rapid USCOM guided individualised treatment has reduced the mortality of septic shock in Bathurst from approximately 50% to less than 5%. This is a 90% mortality reduction with a saving of more than 50 lives per year. Further there was a 90% reduction in emergency transfers from Bathurst of septic shock patients from 2006 to 2012, with emergency transport costs being approximately \$8000 per transfer.

Professor Smith said *“This protocol saves lives and money. Its as simple as that, and there is no reason every Hospital in Australia shouldn’t be adopting this approach to treat septic shock.”*

Executive Chairman of Uscom, Rob Phillips said, *“Professor Smith’s results set new standards by proving that septic shock is curable, and USCOM is central to this management. They treat each patient individually and rapidly, and achieving a less than 5% mortality is unprecedented. If his work were duplicated Australia wide 25,000 lives would be saved per year and many millions of dollars.”*

Sepsis occurs in 1-2% of all hospitalisations and is responsible for up to 25% of all ICU utilisations, effecting over 18million people worldwide annually, and is responsible for the same number of deaths as heart attacks and 9.3% of all US deaths, with a predicted increase in incidence of 1.5% per annum. Global mortality ranges from 30-60% with treatment costs in the order of US\$22,100. A less than 5% in mortality and improvements in the effectiveness of treatment worldwide would have significant health economic consequences.



Uscom Limited
ABN 35 091 028 090
Suite 1, Level 7, 10 Loftus Street
Sydney NSW 2000 Australia
T +612 9247 4144 F +612 9247 8157
www.uscom.com.au

MARKET ANNOUNCEMENT

Bathurst Sepsis Complications 2006-2012




Figure 1: Percentage mortality and renal failure in patients with diagnosed septic shock from ANZICS CORE Adult Database treated at Bathurst Hospital from 2006 to 2012 in annual quarters demonstrating a mortality reduction from 55% to less than 5%.

References:

Australian New Zealand Intensive Care Society Centre for Outcomes and Resource Evaluation adult database.

http://news.bbc.co.uk/2/hi/uk_news/england/nottinghamshire/8525901.stm

Brierley J, Peters MJ. Distinct Hemodynamic Patterns of Septic Shock at Presentation to Pediatric Intensive Care. *Pediatrics* 2008;122:752-759.

Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome and associated costs of care. *Crit Care Med* 2001;29:1303-1310.

About Uscom

Uscom Limited is an Australian medical device company which listed on the Australian Stock Exchange in December 2003. Uscom has developed a Non Invasive Cardiac Output Monitor. The USCOM is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency and Intensive Care Medicine and Anesthesia, and is a tool of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.

USCOM has global regulatory approval and the device is currently marketed in North America, South America, Europe, the Middle East, Australia & New Zealand, China and SE Asia.

Uscom Contacts

Rob Phillips
Executive Chairman
rob@uscom.com.au

Tom Rowe
Company Secretary
secretary@uscom.com.au